This letter refutes the “overdiagnosis” narrative, blaming the stimulant shortage on DEA regulatory failures, clinical constraints, and recognition of historical underdiagnosis.
Gintaras Razaitis, MD
Advertisement
Articles by Gintaras Razaitis, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
Daraxonrasib Clears FDA as First RAS-Targeted Pancreatic Cancer Drug
2
As GLP-1 Costs Climb, Medicare Part D Plans Face a Reckoning
3
ACO-SWITCH to Evaluate Tafamidis-to-Acoramidis Switch in ATTR-CM
4
FAQ: Prior Authorization Reform—Will Changes Go Far Enough by 2027?
5